An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

NCT05013008 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

951

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Type 2 Diabetes Mellitus

Interventions

DRUG: Finerenone (Kerendia, BAY94-8862)
DRUG: Placebo

Sponsor

Bayer